Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Dermatologic 2

Conditions

Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 2

Interventions

hypericin 4zanolimumab 3mogamulizumab 3cobomarsen 3Vorinostat 3Bexarotene 3denileukin diftitox 2Vitamin B 12 2Panobinostat 2Folic Acid 2Amines 2A-dmDT390-bisFv(UCHT1) protein 210-propargyl-10-deazaaminopterin 2talimogene laherparepvec 1resminostat 1ontuxizumab 1navitoclax 1forodesine 1TTI-621 1Radiation 1N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide 1Methotrexate 1Mechlorethamine 1MAC-ST-001 1Interleukin-12 Subunit p35 1Fentanyl 1Fenretinide 1Duration of Therapy 1Drug Therapy 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Mycosis Fungoides × hypericin × Clear all
NCT06470451 2026-04-03

FLASH2

Soligenix

Phase 3 Recruiting
80 enrolled
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT06149247 2025-08-20

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Soligenix

Phase 2 Completed
10 enrolled 7 charts
Lymphoid

Mycosis Fungoides

NCT05380635 2023-06-07

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

Soligenix

Phase 2 Completed
9 enrolled 9 charts
Lymphoid

Mycosis Fungoides

NCT02448381 2022-04-15

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Soligenix

Phase 3 Completed
169 enrolled 13 charts
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡